Related Experiment Video

Updated: Jun 12, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Microcosting of Childhood Hodgkin Lymphoma Treatment Across Resource Levels Using the Adapted Resource and

Sahar Aliabadi1,2, Priyadarshini Kumar3, John T Lucas4

  • 1School of Public Health, University of Alberta, Edmonton, AB, Canada.

JCO Global Oncology
|June 10, 2026
PubMed

Insights

Childhood Hodgkin lymphoma treatment costs vary widely based on resource availability and clinical choices. Understanding these costs is crucial for equitable pediatric cancer care globally.

Area of Science:

  • Pediatric Oncology
  • Health Economics
  • Health Technology Assessment

Background:

  • Childhood Hodgkin lymphoma is a significant pediatric cancer, curable with multimodal therapy.
  • Equitable access to optimal treatment is a global challenge.
  • The Adapted Resource and Implementation Application (ARIA) guidelines offer resource-stratified treatment options.

Purpose of the Study:

  • To analyze the cost implications of clinical decisions within the ARIA framework for childhood Hodgkin lymphoma.
  • To provide data for global decision-making and implementation strategies.
  • To inform equitable care delivery across diverse healthcare systems.

Main Methods:

  • A top-down microcosting analysis was performed from a US payer perspective.
  • An ingredient-based framework guided by ARIA and expert input was utilized.
  • Costs were calculated for pretreatment, treatment, and 5-year follow-up across ARIA risk groups and resource strata (A-E).

Main Results:

  • Total per-patient costs ranged from $24,116 to $189,244 USD.
  • Treatment costs increased with risk level and resource strata, from $6,285-$168,875 USD.
  • Substituting vincristine with brentuximab vedotin significantly increased chemotherapy costs, from $2,510 to $147,118 USD.

Conclusions:

  • This study presents the first ARIA-informed cost analysis for childhood Hodgkin lymphoma.
  • Resource-driven clinical decisions substantially influence treatment costs.
  • The methodology offers a scalable approach for future health technology assessments to support equitable pediatric cancer care investments.
Abstract

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...